Cargando…

Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes

In type 1 diabetes, pancreatic beta cells are destroyed by chronic autoimmune responses. The disease develops in genetically susceptible individuals, but a role for environmental factors has been postulated. Viral infections have long been considered as candidates for environmental triggers but, giv...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunne, Jessica L., Richardson, Sarah J., Atkinson, Mark A., Craig, Maria E., Dahl-Jørgensen, Knut, Flodström-Tullberg, Malin, Hyöty, Heikki, Insel, Richard A., Lernmark, Åke, Lloyd, Richard E., Morgan, Noel G., Pugliese, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450860/
https://www.ncbi.nlm.nih.gov/pubmed/30675626
http://dx.doi.org/10.1007/s00125-019-4811-7
_version_ 1783409081276432384
author Dunne, Jessica L.
Richardson, Sarah J.
Atkinson, Mark A.
Craig, Maria E.
Dahl-Jørgensen, Knut
Flodström-Tullberg, Malin
Hyöty, Heikki
Insel, Richard A.
Lernmark, Åke
Lloyd, Richard E.
Morgan, Noel G.
Pugliese, Alberto
author_facet Dunne, Jessica L.
Richardson, Sarah J.
Atkinson, Mark A.
Craig, Maria E.
Dahl-Jørgensen, Knut
Flodström-Tullberg, Malin
Hyöty, Heikki
Insel, Richard A.
Lernmark, Åke
Lloyd, Richard E.
Morgan, Noel G.
Pugliese, Alberto
author_sort Dunne, Jessica L.
collection PubMed
description In type 1 diabetes, pancreatic beta cells are destroyed by chronic autoimmune responses. The disease develops in genetically susceptible individuals, but a role for environmental factors has been postulated. Viral infections have long been considered as candidates for environmental triggers but, given the lack of evidence for an acute, widespread, cytopathic effect in the pancreas in type 1 diabetes or for a closely related temporal association of diabetes onset with such infections, a role for viruses in type 1 diabetes remains unproven. Moreover, viruses have rarely been isolated from the pancreas of individuals with type 1 diabetes, mainly (but not solely) due to the inaccessibility of the organ. Here, we review past and recent literature to evaluate the proposals that chronic, recurrent and, possibly, persistent enteroviral infections occur in pancreatic beta cells in type 1 diabetes. We also explore whether these infections may be sustained by different virus strains over time and whether multiple viral hits can occur during the natural history of type 1 diabetes. We emphasise that only a minority of beta cells appear to be infected at any given time and that enteroviruses may become replication defective, which could explain why they have been isolated from the pancreas only rarely. We argue that enteroviral infection of beta cells largely depends on the host innate and adaptive immune responses, including innate responses mounted by beta cells. Thus, we propose that viruses could play a role in type 1 diabetes on multiple levels, including in the triggering and chronic stimulation of autoimmunity and in the generation of inflammation and the promotion of beta cell dysfunction and stress, each of which might then contribute to autoimmunity, as part of a vicious circle. We conclude that studies into the effects of vaccinations and/or antiviral drugs (some of which are currently on-going) is the only means by which the role of viruses in type 1 diabetes can be finally proven or disproven.
format Online
Article
Text
id pubmed-6450860
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-64508602019-04-17 Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes Dunne, Jessica L. Richardson, Sarah J. Atkinson, Mark A. Craig, Maria E. Dahl-Jørgensen, Knut Flodström-Tullberg, Malin Hyöty, Heikki Insel, Richard A. Lernmark, Åke Lloyd, Richard E. Morgan, Noel G. Pugliese, Alberto Diabetologia For Debate In type 1 diabetes, pancreatic beta cells are destroyed by chronic autoimmune responses. The disease develops in genetically susceptible individuals, but a role for environmental factors has been postulated. Viral infections have long been considered as candidates for environmental triggers but, given the lack of evidence for an acute, widespread, cytopathic effect in the pancreas in type 1 diabetes or for a closely related temporal association of diabetes onset with such infections, a role for viruses in type 1 diabetes remains unproven. Moreover, viruses have rarely been isolated from the pancreas of individuals with type 1 diabetes, mainly (but not solely) due to the inaccessibility of the organ. Here, we review past and recent literature to evaluate the proposals that chronic, recurrent and, possibly, persistent enteroviral infections occur in pancreatic beta cells in type 1 diabetes. We also explore whether these infections may be sustained by different virus strains over time and whether multiple viral hits can occur during the natural history of type 1 diabetes. We emphasise that only a minority of beta cells appear to be infected at any given time and that enteroviruses may become replication defective, which could explain why they have been isolated from the pancreas only rarely. We argue that enteroviral infection of beta cells largely depends on the host innate and adaptive immune responses, including innate responses mounted by beta cells. Thus, we propose that viruses could play a role in type 1 diabetes on multiple levels, including in the triggering and chronic stimulation of autoimmunity and in the generation of inflammation and the promotion of beta cell dysfunction and stress, each of which might then contribute to autoimmunity, as part of a vicious circle. We conclude that studies into the effects of vaccinations and/or antiviral drugs (some of which are currently on-going) is the only means by which the role of viruses in type 1 diabetes can be finally proven or disproven. Springer Berlin Heidelberg 2019-01-23 2019 /pmc/articles/PMC6450860/ /pubmed/30675626 http://dx.doi.org/10.1007/s00125-019-4811-7 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle For Debate
Dunne, Jessica L.
Richardson, Sarah J.
Atkinson, Mark A.
Craig, Maria E.
Dahl-Jørgensen, Knut
Flodström-Tullberg, Malin
Hyöty, Heikki
Insel, Richard A.
Lernmark, Åke
Lloyd, Richard E.
Morgan, Noel G.
Pugliese, Alberto
Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes
title Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes
title_full Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes
title_fullStr Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes
title_full_unstemmed Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes
title_short Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes
title_sort rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes
topic For Debate
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450860/
https://www.ncbi.nlm.nih.gov/pubmed/30675626
http://dx.doi.org/10.1007/s00125-019-4811-7
work_keys_str_mv AT dunnejessical rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes
AT richardsonsarahj rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes
AT atkinsonmarka rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes
AT craigmariae rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes
AT dahljørgensenknut rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes
AT flodstromtullbergmalin rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes
AT hyotyheikki rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes
AT inselricharda rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes
AT lernmarkake rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes
AT lloydricharde rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes
AT morgannoelg rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes
AT pugliesealberto rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes